Seven years on from Sutent and renal cell cancer still needs biomarkers
This article was originally published in Scrip
Renal cell carcinoma (RCC) treatment is in dire need of relevant biomarkers. With the availability of numerous treatment options in RCC, clinicians are faced with the daunting task of determining the optimal approach with barely any clues as to what will work best. And with 63 drugs in the RCC pipeline, as identified by new analysis from Datamonitor Healthcare, Pipeline: Renal Cell Cancer, the situation is only set to get more complicated.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.